Overall, cellular and molecular studies have shown that PBMT can ameliorate glutamatergic dysfunction in depressive-like mouse models by improving glutamate uptake mediated by GLT-1 and glutamate receptor activity, ultimately achieving the effects of reducing glutamate excitotoxicity, increasing cell activity, and improving depression-like behaviors. The gene discussed is SLC1A2; the disease is depressive symptom measurement.